Algorithms for adult outpatient care of coronavirus disease 2019 (COVID-19) and its Assumption

Livzan, M. А.; Драпкина, О. М.; Николаев, Н. А.; Skirdenko, Yu. P.; Shepel, R. N.; Викторова, И. А.; Kuznetsova, Maryna; Мордык, А. В.; Andreev, Katerina; Berezhnoy, V. G.; Вершинина, М. В.; Gorbenko, A. V.; Друк, И. В.; Korennova, O. Yu.; Костенко, М. Б.; Лисичкина, А. В.; Nadey, E. V.; Ovsyannikov, N. V.; Пузырева, Л. В.; Толох, И. М.; Fedorin, M. M.

doi:10.15829/1728-8800-2021-2916

Cited by 6 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We attributed it to the guidelines having a vague and not clearly defined objective. The CPGs by ROPNIZ [16] and MGNOT [20] score for Scope and Purposes. The population was clearly described and the purpose was well defined and worded here.…”

Section: Results Of Cpgs Assessment Domain Scoresmentioning

confidence: 99%

“…The range of scores was 31-67% (See Appendix H-Section assessment results STAKE-HOLDER INVOLVEMENT). The CPG by NIIOZMM [19] received the lowest score (31%) and the CPG by ROPNIZ [16] received the highest score-67%.…”

Section: Results Of Cpgs Assessment Domain Scoresmentioning

confidence: 99%

“…We assigned a relatively low score (31%) to the NIIOZMM [19] for the domain Stakeholder Involvement as it did not include any specifications about the target audience. The experts pointed out that epidemiologists and medical statisticians should have been included in the development of the CPGs of NIIOZMM [19] The ROPNIZ CPGs [16] received the highest score (67%) for the domain Stakeholder Involvement (See Appendix H-Section assessment results STAKEHOLDER INVOLVE-MENT). The variety of specialists involved in the development of these guidelines was better than in all other identified CPGs.…”

Section: Results Of Cpgs Assessment Domain Scoresmentioning

confidence: 99%

“…The lowest score for the domain Rigour of Development we attributed to the ROP-NIZ [16] (See Appendix H-Section assessment results RIGOUR OF DEVELOPMENT).…”

Section: Results Of Cpgs Assessment Domain Scoresmentioning

confidence: 99%

“…The fourth domain Clarity of Presentation consists of three items (items [15][16][17]. Clarity of presentation is focused on the way the CPG is written, specifically its language, format, and structure.…”

Section: Results Of Cpgs Assessment Domain Scoresmentioning

confidence: 99%

See 4 more Smart Citations

Direct Oral Anticoagulants’ Consumption and Expenditure in the COVID-19 Pandemic in Russia and Clinical Practice Guidelines for Their Use

Baybulatova,

Chenkurov,

Korovyakova

et al. 2023

Pharmacoepidemiology

View full text Add to dashboard Cite

Background: The coronavirus pandemic has led to the creation of clinical guidelines by a large number of professional medical communities. However, the quality and methodology of development of Russian clinical guidelines has been little studied. The continued relevance of studying the use of DOACs (Direct oral anticoagulants) in patients with COVID-19 was the basis for conducting this study. Aim: The objective of this study was to assess DOAC consumption and expenditure in the Russian Federation during the COVID-19 pandemic and to analyze whether it was supported by the domestic evidence base for the use of DOACs in COVID-19 patients through identifying all publicly available Russian-produced CPGs (Clinical practice guidelines) for the treatment of COVID-19 and assessing their quality as the source of recommendations for the use of oral anticoagulants for the prevention of thrombotic complications in COVID-19 patients. We searched Russian databases for CPGs, published between 2020 and 2023. We identified seven relevant documents that met our inclusion criteria. Three authors analyzed Russian clinical guidelines using an AGREE II questionnaire. We calculated DOAC DDD (defined daily dose) consumption according to Russian clinical guidelines and DDD consumption in patients with COVID-19 for the period 2020–2022. Results: Seven clinical CPGs were analyzed with the AGREE II tool. It was revealed that experts gave the highest scores for the sections on scope and purpose (from 62.98% to 100%), and clarity of presentation (from 96.30% to 100%). The lowest scores were given for the sections on stakeholder involvement (33.33% to 64.81%), rigour of development (from 0% to 49.31%), applicability (from 23.61% to 50%), and editorial independence (from 0% to 50%). When comparing the total score, it was found that two clinical guidelines received the highest scores—ROPNIZ (Livzan), and ROPNIZ (Drapkina). The minimum score was registered with the NIIOZMM (Khripun) clinical guideline. No guideline received a total score of more than 70%. According to clinical recommendations, the consumption of apixaban and rivaroxaban is 15 DDD (30-day course of therapy), or 22.5 DDD (45-day course of therapy). Consumption of apixaban in the Russian Federation in 2020 and 2021 corresponds to the indicators presented in clinical recommendations (in 2020—26.59 DDD per patient with COVID-19; in 2021—15.75 DDD per patient with COVID-19), and in 2022—10.67 DDD, which is below the recommended values. In 2020, consumption of rivaroxaban in the Russian Federation was 26.59 which corresponds to data from clinical recommendations; in 2021, consumption decreased to 7.87 DDD; in 2022 it decreased to 5.48 DDD, which is 2.74 times less than recommended. Conclusions: Analysis of seven clinical recommendations revealed that such sections of clinical recommendations as scope, purpose, and clarity of presentation had the highest degree of assessment in accordance with AGREE II. The lowest scores were given for the sections on stakeholder involvement, rigour of development, applicability, and editorial independence. When comparing the total score, it was found that two clinical guidelines received the highest scores—the Russian Society for the Prevention of Non-communicable Diseases (Livzan), and the Russian Society for the Prevention of Non-communicable Diseases (Drapkina). The minimum score was registered with the Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department clinical guideline. No guideline received a total score of more than 70%. During the pandemic, the highest DDD consumption of DOACs was in 2020, which exceeded the DOACs’ recommended DDD by Russian clinical guidelines. DOAC consumption had decreased by 2022. There was a decrease in the consumption of rivaroxaban, with an increase in apixaban’s share in the structure of DOAC consumption during the coronavirus pandemic. Obtained data indicate that in 2021 the apixaban consumption in the Russian Federation corresponded to the recommended DDD in the national guidelines, which indicates the most correct use of apixaban according to Russian GPGs.

show abstract

Section: Results Of Cpgs Assessment Domain Scoresmentioning

confidence: 99%

Section: Results Of Cpgs Assessment Domain Scoresmentioning

confidence: 99%

Section: Results Of Cpgs Assessment Domain Scoresmentioning

confidence: 99%

“…The lowest score for the domain Rigour of Development we attributed to the ROP-NIZ [16] (See Appendix H-Section assessment results RIGOUR OF DEVELOPMENT).…”

Section: Results Of Cpgs Assessment Domain Scoresmentioning

confidence: 99%

Section: Results Of Cpgs Assessment Domain Scoresmentioning

confidence: 99%

See 3 more Smart Citations

Direct Oral Anticoagulants’ Consumption and Expenditure in the COVID-19 Pandemic in Russia and Clinical Practice Guidelines for Their Use

Baybulatova,

Chenkurov,

Korovyakova

et al. 2023

Pharmacoepidemiology

View full text Add to dashboard Cite

show abstract

Long-term dynamics of the levels of anti-SARS-CoV-2 S-protein IgG antibodies in vaccinated individuals

Drapkina¹,

Бернс²,

Gorshkov³

et al. 2022

Cardiovasc Ther Prev

Self Cite

View full text Add to dashboard Cite

In the context of the ongoing coronavirus disease 2019 (COVID-19) pandemic, it is extremely important to study immunogenicity and immune response duration in different vaccines.Aim. As part of a prospective observational study, to study the levels of anti-SARS-CoV-2 S-protein IgG antibodies in individuals vaccinated with the Gam-COVID-Vac and CoviVac vaccines.Material and methods. The data of 93 people who completed the first 3 visits were analyzed, 23 of whom were vaccinated with the Gam-COVID-Vac vaccine and 70 people — with the CoviVac vaccine. We collected blood before the injection of vaccine doses I and II, as well as 42 days after the injection of dose I in order to quantitatively determine IgG levels. The level of anti-SARS-CoV-2 S-protein IgG antibodies was determined using the SARS-CoV-2 IgG ELISA-BEST reagent kit on the InfiniteF50 TECAN system.Results. A significant increase in anti-SARS-CoV-2 S-protein IgG antibodies was observed in those vaccinated with Gam-COVID-Vac. In the group of CoviVac vaccine, an increase in the level anti-SARS-CoV-2 S-protein IgG antibodies in absolute values was recorded, however, this increase did not reach statistical significance.Conclusion. The data obtained show that the level of anti-SARS-CoV-2 S-protein antibodies 42 days after Gam-COVID-Vac vaccination is significantly higher than after CoviVac vaccination. However, an increase in the level of IgG in both groups indicates the ability of both vaccines to stimulate the production of anti-SARS-CoV antibodies.

show abstract

MARKIZ study: screening for post-COVID-19 syndrome using a questionnaire to identify symptoms and risk factors for noncommunicable diseases

Николаев

Drapkina²,

Ливзан

et al. 2023

Cardiovasc Ther Prev

Self Cite

View full text Add to dashboard Cite

Aim. To provide data on the diagnostic and prognostic value of questionnaire survey for post-COVID-19 syndrome during screening and regular medical check-ups of employees, as well as preventive medical examinations.Material and methods. This single-center cross-sectional comparative study involved 1120 people (92,1% of the general population — all employees of the organization), including 195 men (67,3% of the general population) and 925 women (79,5% of the general population). All participants filled out the post-COVID-19 syndrome (PS) detection questionnaire, the Hospital Anxiety and Depression Scale and the QAA-25p Adherence Assessment Questionnaire. Potential adherence to treatment was calculated using the SCOPA software. Statistical processing was performed using tools adapted for medical and biomedical research (Python language; Sklearn, NumPy, Pandas libraries) and Statistica 6.13 (StatSoft Inc., USA).Results. As a result, 47% of respondents noted at least one symptom that reduces the quality of life and/or performance efficacy. In all subsamples, women reported symptoms more frequently than men. The most informative indicators associated with post-COVID-19 syndrome are age (Mann-Whitney U test, p=0,042), number of PS symptoms (Mann-Whitney U test, p=0,001), severity of PS symptom (Mann-Whitney U test, p= 0,004) and adherence to health care (Kruskal-Wallis H test, p=0,021). An increased level of anxiety is associated with all the analyzed symptoms, depression level with 6 symptoms, age with 5 symptoms, insufficient compliance with 3 symptoms.Conclusion. PS questionnaire should be included in a comprehensive survey program of persons undergoing medical examinations. It is necessary to develop algorithms for the treatment and diagnosis of patients that take into account the number and severity of individual symptoms separately for men and women with consideration to their COVID-19 epidemiological status, as well as age and markers of anxiety, depression, and adherence to treatment.

show abstract

Algorithms for adult outpatient care of coronavirus disease 2019 (COVID-19) and its Assumption

Abstract: The paper presents algorithms for adult outpatient care of coronavirus disease 2019 (COVID-19) and its assumption.

Cited by 6 publications

References 0 publications

Direct Oral Anticoagulants’ Consumption and Expenditure in the COVID-19 Pandemic in Russia and Clinical Practice Guidelines for Their Use

Direct Oral Anticoagulants’ Consumption and Expenditure in the COVID-19 Pandemic in Russia and Clinical Practice Guidelines for Their Use

Long-term dynamics of the levels of anti-SARS-CoV-2 S-protein IgG antibodies in vaccinated individuals

MARKIZ study: screening for post-COVID-19 syndrome using a questionnaire to identify symptoms and risk factors for noncommunicable diseases

Contact Info

Product

Resources

About